Shorter steroid treatment for steroid-sensitive nephrotic syndrome
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether a shorter course of steroids works as well as the usual longer course for adults with steroid-sensitive nephrotic syndrome, a kidney condition that causes protein leakage and swelling. If you respond quickly to initial steroid treatment, you may be able to take steroids for less time, reducing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 16 years or older.
- You have nephrotic syndrome with very high protein in your urine (protein-to-creatinine ratio of 3000 mg/g or more).
- Your blood albumin (a protein) level is below 30 g/L.
- You have not taken steroids or other immune-suppressing drugs for kidney disease before (except for the first 28 days of standard prednisolone treatment).
- Your nephrotic syndrome is not caused by another disease (like diabetes or lupus).
- You achieved complete remission within 4 weeks of starting standard prednisone or prednisolone treatment.
- You do not have any condition that prevents you from taking steroids, and you have not had allergic reactions to steroids before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an injection (SG301) that targets a protein called CD38 to help children whose nephrotic syndrome keeps coming back or depends on steroids. The goal is to see if the treatment can reduce relapses and the need for steroids.
This trial tests whether a drug called rituximab can help children with their first episode of nephrotic syndrome stay in remission longer. It is for children who have already responded to steroid treatment.
This trial tests if a hormone called ACTH can help children with nephrotic syndrome who have frequent relapses or need steroids to stay in remission. It aims to find a treatment that may reduce the need for steroids and prevent relapses.
This trial looks at whether people with proliferative lupus nephritis can use less steroid medicine while still controlling kidney inflammation. It may help reduce steroid side effects, while testing a carefully monitored treatment plan.
This study looks at children newly diagnosed with nephrotic syndrome to understand how genes and proteins in the blood might predict the disease's course and response to treatment. By collecting samples, researchers hope to find markers that could guide better, more personalized care for future patients.
This trial tests whether a lower starting dose of steroids can control kidney inflammation in children with lupus nephritis. It aims to reduce side effects while still treating the disease effectively.
Hear when a new Idiopathic Nephrotic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.